Adenosine receptor A3 (A3) regulates directed movement of polymorphonuclear cells (PMNs) to sites of inflammation and has been implicated as a relevant mediator in models of inflammatory diseases. Here, we sought to characterize the role of A3 in a murine model of lung inflammation. Initial studies revealed that pulmonary A3 transcript levels were 
Introduction
Acute lung injury (ALI) is a life-threatening disorder with significant adverse impact on morbidity and mortality of critically ill patients. As recent epidemiological studies indicate, ALI leads to 75,000 deaths annually in the United States (47) . Respiratory failure is caused by an excessive inflammatory response to both pulmonary and extrapulmonary stimuli, including pneumonia, acid aspiration, ischemia / reperfusion, and sepsis. Inflammatory mediators can disrupt the pulmonary capillary barrier, leading to the influx of a proteinrich edema (58) with severe consequences for gas exchange and the functional integrity of remote organ systems.
Excessive infiltration of polymorphonuclear leukocytes (PMNs) into the lungs has been identified as a pivotal event in the early development of ALI. In various experimental models of lung injury, depletion of PMNs markedly attenuated the severity of lung damage (1) . In addition, pulmonary function in patients suffering from ALI negatively correlates with neutrophil counts in the blood (2) . PMN recruitment occurs in a cascade-like sequence of activation, sequestration in pulmonary vessels, transendothelial, and transepithelial migration (40). Each migration step is regulated by distinct molecules (39), and the importance of investigating discrete steps of PMN migration in the lung has been emphasized (7). Although neutrophil infiltration has been recognized as a hallmark of ALI, the molecular mechanisms underlying PMN trafficking in the lung still remains incompletely understood. Current therapeutic options are limited to mechanical ventilation with low tidal volumes and other supportive approaches. A specific pharmacotherapy is lacking (58) .
Besides other molecule families (3; 43; 44), extracellular adenosine is an essential mediator of endothelial barrier integrity (20) and leukocyte trafficking to inflammatory sites (21) . Adenosine is released in response to various stimuli, including hypoxia, tissue damage, or chronic inflammation (5) .
Adenosine signals through four subtypes of G protein-coupled adenosine receptors (A1, A2a, A2b, and A3) that are ubiquitously expressed on various hematopoietic and non-hematopoietic cells. Each type of adenosine receptor exhibits a distinct pharmacological and physiological profile (15) . Activation of adenosine receptors (AR) induces a variety of cell responses through changes in intracellular levels of cAMP, diacylglycerol, and inositol triphosphate. Recent studies identified CD39 and CD73, both rate-limiting enzymes for the generation of extracellular adenosine, as critical mediators in pulmonary inflammation (8; 45).
While adenosine receptors A2a and A2b have been recognized as important mediators in inflammatory models (9; 41), adenosine receptor A3 has received less attention so far. Adenosine receptor A3 is expressed in a broad spectrum of tissues, most abundantly in lung and liver (49) . A3 signals through Gi, inhibits adenylate cyclase and activates phospholipase C (33). In addition, A3 binds to mitogen-activated protein kinases (MAPKs) (52). Upon activation, A3 is rapidly phosphorylated and desensitized (33). Physiologic functions of A3 signaling include mediator release from mast cells and preconditioning (14) . The role of A3 in inflammation has been controversial.
A3 is involved in directing PMNs to sites of inflammation. Exposure to chemotactic signals leads to upregulation of A3 and translocation from cytosolic granules to the cell surface near the leading edge (6). In some studies, cells that lack A3 lose their ability to effectively migrate towards a chemotactic gradient in vitro and in vivo (6; 27). In contrast, others have found that not inhibition but activation of A3 diminished migration of leukocytes to sites of inflammation (54). In a sepsis model, A3-/-mice exhibited impaired renal and liver function and had a worse 7-day survival compared with wildtype mice. Treatment with an A3 agonist was sufficient to improve organ function and survival in wildtype mice (30). In the lung, activation of A3 protects from ischemia/reperfusion-induced tissue damage (36; 46). In addition, A3 has been implicated in suppressing LPS-induced release of chemotactic cytokines (32; 35), a key event in the early phase of lung inflammation.
We therefore hypothesized that activation of A3 would reduce PMN infiltration in the lungs by inhibiting the release of chemotactic cytokines into the alveolar space. In a murine model of LPS-induced lung injury, we determined the role of A3 for the different migration steps in the lung. Our experimental approach involved pharmacologic activation of A3 and the use of A3 gene-deficient (A3-/-) and chimeric mice. We further determined the effects of A3 in the integrity of the pulmonary endothelium and identified the target cell of a specific A3 agonist by means of in vitro transmigration assays. 7 only) and BM from wildtype into A3-/-mice (chimeric mice express A3 on hematopoietic cells only). To confirm efficacy of radiation, sentinel mice did not receive BM. This regimen leads to an almost complete reconstitution (> 95%) of mice with donor-derived blood after 6 weeks (40). In addition, we transplanted A3-/-bone marrow into A3-/-mice to account for potential effects of the radiation procedure. Chimeric mice were housed in individually ventilated cages for at least 6 weeks before experiments, and antibiotics (5 mM sulfamethoxazole and 0,86 mM trimethoprim) were added to drinking water alternating semi-weekly.
Murine model of acute lung injury
To induce an acute pulmonary inflammation, we exposed mice to aerosolized lipopolysaccharide (LPS) in a custom-built chamber. LPS from Salmonella enteritidis (Sigma-Aldrich) was dissolved in sterile saline (500 μg/ml) and aerosolized by an air nebulizer that was connected to the chamber. Mice were allowed to inhale LPS for 30 min. As previously shown (40; 43), LPSinhalation induces pulmonary inflammation with several characteristics of acute lung injury, including PMN trafficking into all compartments of the lung, increase in microvascular leakage, release of chemotactic cytokines, and lung tissue damage (42).
A3 mRNA Expression
Real-time RT-PCR was performed to determine LPS-induced expression of A3 mRNA in whole lung tissue. Wildtype mice inhaled LPS aerosol, and lungs were harvested at indicated times. Control animals did not inhale LPS. Lungs were perfused free of blood, excised, and stored in RNAlater (Ambion) at -80°C. Total RNA was isolated from lung homogenates and reverse transcription was performed using SuperScript III Transcriptions kit (Invitrogen) and oligo(dT) primers. cDNA samples analyzed with primers for A3 (5′-GCTGCCATCGGGCTCTGTG-3' and 5'-GCAGGCATAGAAGTGCATCT-3') on an iCycler iQ Real-Time Detection System (Bio-Rad). Values were determined using the iCycler iQ Real-Time Detection System Software, version 3.1 (Bio-Rad). Murine β-actin mRNA (primers, 5'-ACATTGGCATGGCTTTGTTT-3' and 5'-GTTTGCTCCAACCAACTGCT-3') was amplified in identical reactions to control for the amount of starting template.
Pharmacological activation of A3
The selective A3 agonist, 2-chloro-N(6)- PMNs that were not reached by the injected antibody (40).
Differential blood counts
To reveal a potential effect of CI-IB-MECA on the release of PMNs from the bone marrow that might have interfered with the analyses of our migration studies, we performed differential blood counts in mice that were treated with CI-IB-MECA.
Immunohistochemistry
Wildtype and A3-/-mice were anesthetized 24 h after LPS inhalation with or without pretreatment with Cl-IB-MECA. Control mice did not receive LPS. The pulmonary circulation was perfused free of blood, the trachea was cannulated, and the lung was inflated with 4% paraformaldehyde (PFA) for 10 min at 25 cmH2O. The lungs were subsequently removed and fixed in PFA for 24 hours.
Paraffin-embedded sections (5 µm) were stained for PMNs using the avidinbiotin technique (Vector Laboratories) as previously described (4) . Briefly, lung sections were deparaffinized, rehydrated, and nonspecific binding was blocked by incubation with avidin, 10% rabbit serum, and 0.5% fish skin gelatin oil (FSGO). Sections were washed with PBS and incubated overnight with a specific antibody to mouse neutrophils (clone 7/4; Caltag Laboratories) (24). Biotinylated rabbit anti-rat IgG (5 g/ml Vector Laboratories) was added and incubated for 1 h, followed by avidin-biotin-peroxidase complexes (Vectastain Elite ABC kit; Vector Laboratories), washed with PBS, incubated with diaminobenzidine (DAB kit; Vector Laboratories), and counterstained with hematoxylin.
Chemokine release measurements
Release of CXCL1 (keratinocyte-derived chemokine, KC), CXCL2/3 (macrophage inflammatory protein-2, MIP-2), tumor necrosis factor-α (TNFα), and interleukin-6 (IL-6) into the BAL of wildtype and A1-/-mice was determined by enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN) three hours upon LPS inhalation. Some animals were pretreated with Cl-IB-MECA 30 min prior to LPS exposure. Negative controls received no LPS.
A3-dependent pulmonary microvascular leakage
Microvascular leakage was assessed 6 hours after LPS inhalation by the Evans blue dye extravasation technique (19) . Evans Blue (20 mg/kg; SigmaAldrich, Steinheim, Germany) was injected into the tail vein 30 minutes before thoracotomy. The pulmonary vasculature was perfused with phosphatebuffered saline through the beating right ventricle to remove intravascular dye.
Lungs were excised, homogenized and Evans blue extracted as described previously (38). The absorption of Evans blue was determined spectrophotometrically at 620 nm and corrected for the presence of heme pigments: A620 (corrected) = A620 -(1.426 x A750 + 0.030). The amount of Evans blue in lung homogenates was calculated against a standard curve (micrograms Evans blue dye per lung) (19) . Some animals received Cl-IB-MECA (100µg/kg) 30 min before LPS exposure. Control animals did not received LPS.
Cytoskeletal remodelling
To evaluate whether A3 is involved in cytoskeletal remodeling of pulmonary endothelial cells, we investigated the distribution of F-actin as described previously (43; 51). Briefly, HMVEC-L cells were allowed to adhere on gelatincoated glass coverslips overnight (medium with 10% FBS). Cells were then serum-starved for six hours and stimulated with LPS (100ng/ml) in presence or absence of Cl-IB-MECA (100 ng/ml). Untreated cells served as control. At indicated times, cells were washed, fixed (4% PFA), permeabilized (0.1% Triton X-100, Sigma Co., St. Louis, MO), and stained with FITC-phalloidin and DAPI Nucleic Acid Stain (both Invitrogen) . Coverslips were mounted on glass slides and microscopy was performed on a confocal fluorescence microscope (LSM 510, Zeiss, Göttingen, Germany). 
In vitro transmigration

Statistical analysis
Statistical analysis was performed with GraphPad Prism (version 5.0; GraphPad, San Diego, CA). Differences between the groups were assessed by a one-way ANOVA followed by a post hoc Tukey's test. Studies that compared the effect of two factors were analyzed by a two-way ANOVA. Data are presented as mean ± SD, P < 0.05 was considered statistically significant.
Results
Blood counts
Genetically altered mice sometimes exhibit increased leukocyte counts in the peripheral blood that may interfere with PMN trafficking and inflammatory response. To reveal such differences, differential blood cell count was performed in wildtype and A3-/-mice. Analyses revealed similar cell counts of all types of leukocytes (Table 1) .
LPS induces A3 transcription in the lung
Real-time RT-PCR was performed to reveal LPS-induced transcription of A3 mRNA in the lungs. LPS exposure induced time-dependent A3 mRNA expression. 3 hours after LPS exposure, A3 mRNA expression was ~6-fold (P < 0.05, Figure 1 ).
Cl-IB-MECA attenuates LPS-induced PMN trafficking in the lung
The effect of Cl-IB-MECA on the migration of PMNs into the different 
Cl-IB-MECA does not increase number of circulating PMNs
Adenosine plays a major role in the regulation of hematopoiesis. To reveal potential effects of Cl-IB-MECA on the numbers of circulating PMNs that might have interfered with the analyses of our migration studies, differential blood counts were performed at different time points after Cl-IB-MECA treatment.
CI-IB-MECA did not de-or increase numbers of circulating PMNs, indicating that the effects of CI-IB-MECA on pulmonary PMN trafficking was not caused by altered numbers of circulating PMNs (Figure 4 ).
Quantitative FACS data were illustrated by immunohistochemistry as shown in Figure 5 .
Activation of A3 reduces LPS-induced release of chemotactic cytokines
The release of chemotactic cytokines into the alveolar airspace initiates the recruitment of inflammatory cells into the lungs. To evaluate the effect of A3
on LPS-induced release of cytokines, levels of CXCL1, CXCL2/3, TNFα, and IL-6 were determined in the BAL of wildtype and A3-/-mice. At baseline (no LPS), cytokine levels were undetectable in both groups. LPS exposure induced a significant release of all four cytokines in wildtype and A3-/-mice ( Figure 6 ). In A3-/-mice, LPS-induced release of CXCL2/3 and CXCL1 was higher than in wildtype mice (3900 ± 200 vs. 1400 ± 400 pg/ml; P < 0.05 and 2100 ± 300 vs. 1600 ± 200 pg/ml; P < 0.05). No difference between both groups was found for TNFα and IL-6. Pretreatment with Cl-IB-MECA significantly diminished the release of TNFα and IL-6 in wildtype mice (900 ± 400 vs. 2700 ± 600 pg/ml; P < 0.05 and 100 ± 50 vs. 500 ± 100 pg/ml; P < 0.05). Cl-IB-MECA had no effect in A3-/-mice, confirming the specificity of this compound.
Effects of A3 on hematopoietic versus non-hematopoietic cells
Next, we sought to define the contribution of A3 on hematopoietic versus nonhematopoietic cells for PMN trafficking by generation of chimeric mice.
Consistent with our initial studies in wildtype and A3-/-mice, we did not observe differences in PMN counts between both groups of chimeric mice ( Figure 7) . Surprisingly, pretreatment with Cl-IB-MECA did not alter PMN accumulation in any lung compartment. This finding was in contrast to the results of our studies in wildtype mice ( Figure 2 ) and suggests that in vivo, Cl-IB-MECA requires both cell types to be effective at modulating pulmonary PMN trafficking. A3-/-mice that had been reconstituted with bone marrow from A3-/-mice served as control. PMN trafficking in these mice was not different from A3-/-mice that had not been radiated, confirming previous reports (43) demonstrating that the radiation procedure alone has no effect on PMN migration (data not shown).
Cl-IB-MECA ameliorates LPS-induced microvascular leakage
Increased microvascular leakage is one of the hallmarks of acute pulmonary inflammation. We quantified microvascular permeability by the Evans blue extravasation dye technique. Baseline permeability was not different between wildtype and A3-/-mice. LPS-inhalation induced a significant extravasation of Evans blue in the lungs of wildtype (200 ± 66 vs. 49 ± 26 µg/g lung; P < 0.05) and A3-/-mice (180 ± 35 vs. 72 ± 52 µg/g lung; P < 0.05) (Figure 8 ).
Pretreatment with Cl-IB-MECA reduced Evans blue extravasation in wildtype mice completely (45 ± 13 µg/g lung; P < 0.5). In A3-/-mice, Cl-IB-MECA had no effect on microvascular permeability.
Cytoskeletal remodeling
After we had established a role of A3 for preventing LPS-induced microvascular permeability, we hypothesized that activation of A3 would 
A3 on PMNs mediates in vitro migration of human PMNs
To translate the findings of our studies to the human cell system, we evaluated the effect of Cl-IB-MECA on chemokine-induced migration of human PMNs across a monolayer of HMVEC-L or A549 cells. Activation of A3
on PMNs resulted in a significant decrease in transendothelial migration (10 ng/ml: 30,000 ± 1,000 vs. 86,000 ± 2,000; 1 ng/ml: 28,000 ± 6,000 vs.
86,000 ± 2,000; 0.1 ng/ml: 26,000 ± 10,000 vs. 86,000 ± 2,000; all P < 0.05) Similar results were obtained in appropriate chemotaxis experiments with A549 cells. Pharmacologic activation of A3 on PMNs reduced transepithelial migration significantly (10 ng/ml: 37,000 ± 1,000 vs. 414,000 ± 24,000;
1 ng/ml: 24,000 ± 1,000 vs. 414,000 ± 24,000; 0.1 ng/ml: 18,000 ± 6,000 vs.
414,000 ± 24,000; all P < 0.05) (Figure 11 
Evidence for a significant involvement of A3 in pulmonary inflammation
originates from studies demonstrating that A3 is highly expressed in the lung (49) and mRNA transcription in lung tissue is upregulated upon inflammatory stimuli (37). In the present study, LPS inhalation also increased A3 mRNA in lung homogenates. Pharmacologic activation of A3 has been widely used to demonstrate protective effects of A3 in pulmonary inflammation. In an in vivo model of ischemia/reperfusion-induced lung injury, pretreatment with selective A3 agonists reduced organ damage, edema formation, apoptosis, and leukocyte infiltration as assessed by myeloperoxidase activity (46) . These protective effects were associated with the upregulation of ERK1/2 (36).
These results are consistent with the present study supporting a specific role of A3 in regulating PMN trafficking and microvascular permeability. 
